Compare

BPC-157 (Oral) vs GHK-Cu

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

BPC-157 (Oral)

26 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 97% · Mixed 3% · Unfavorable overall 0%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery
157

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Digestive upset
4

Self-reported dose per injection

Median bucket: 0.6–1 mg · Most common: 1–2 mg

Reports span 0.2–2 mg

0.2–0.4 mg
50
0.4–0.6 mg
6
0.6–1 mg
49
1–2 mg
52

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

How repeat users are trending

Among repeat reporters, 90% said they felt similar to their last entry, 10% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 215 days · Based on 20 repeat reporters

GHK-Cu

120 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 3% · Mixed 97% · Unfavorable overall 0%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Mood
226
Recovery
226
Energy
1

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Injection site irritation
222

Self-reported dose per injection

Median bucket: 2–3 mg · Most common: 2–3 mg

Reports span 0 to ≥ 5 mg (open-ended top bucket)

0–0.01 mg
1
0.025–0.05 mg
16
0.2–0.4 mg
4
0.6–1 mg
1
1–2 mg
71
2–3 mg
87
3–5 mg
43
5+ mg
5

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

How repeat users are trending

Among repeat reporters, 89% said they felt similar to their last entry, 11% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 46 days · Based on 45 repeat reporters

Sources (10)

Published sources linked on the BPC-157 (Oral) and GHK-Cu wiki pages.

  1. PubMed

    Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (review)

    Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018

    Source
    Wiki study page →
  2. PubMed

    Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract

    Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018

    Source
    Wiki study page →
  3. PubMed

    Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions

    Ilic S, Drmic D, Franjic S, et al. Life sciences. 2011

    Source
    Wiki study page →
  4. PubMed

    Stable gastric pentadecapeptide BPC 157 in honeybee (Apis mellifera) therapy, to control Nosema ceranae invasions in apiary conditions

    Tlak Gajger I, Ribarić J, Smodiš Škerl M, et al. Journal of veterinary pharmacology and therapeutics. 2018

    Source
    Wiki study page →
  5. Review Article

    GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes

    Pickart L, Margolina A. Cosmetics. 2018

    Source
    Wiki study page →
  6. PubMed

    GHK peptide as a natural modulator of multiple cellular pathways

    Pickart L, Margolina A. Biomed Res Int. 2014

    Source
    Wiki study page →
  7. ClinicalTrials.gov

    GHK-Cu copper peptide studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  8. PubMed

    GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration

    Pickart L, Vasquez-Soltero JM, Margolina A. BioMed research international. 2015

    Source
    Wiki study page →
  9. PubMed

    Biomimetic Hydrogel Scaffolds with Copper Peptide-Functionalized RADA16 Nanofiber Improve Wound Healing in Diabetes

    Yang X, Zhang Y, Huang C, et al. Macromolecular bioscience. 2022

    Source
    Wiki study page →